This industry-sponsored symposium, held at ESTS 2025, is a medical education activity that is organised and funded by the medical department of Bristol Myers Squibb.
In this symposium, Frank Griesinger, Cecilia Pompili, and Jesme Fox discussed the latest evidence for neoadjuvant and perioperative I-O treatment for patients with resectable NSCLC and clinical- and patient-related factors that influence real-world application of evidence into practice.
The panel also discussed their experiences navigating shared decision-making in current clinical practice for resectable NSCLC and the role of patient advocacy in improving outcomes.
Speakers
Frank Griesinger1
Cecilia Pompili2
Jesme Fox3
1. Faculty of Medicine, University of Oldenburg-European Medical School Director, Dept. of Hematology & Oncology, Pius-Hospital Oldenburg, Germany
2. University of Leeds, England, UK Assoc. Professor in Psychological Oncology and Honorary Consultant Thoracic Surgeon, University of Hull, UK
3. MBA Secretary, Global Lung Cancer Coalition Medical Director, Roy Castle Lung Cancer Foundation Liverpool, UK
